2018年10月08日

KENYA’S BREAKTHROUGH IN NEW TB DRUGS.


Much as WHO approved new Tuberculosis drugs in 2013, Bedaquiline and Delamanid, only a few patients are using them in the country.

Bedaquiline and Delamanid were approved in US to treat patients with extremely drug-resistant tuberculosis (XDR-TB) and Multi-drug resistant tuberculosis (MDR-TB). World Health Organization (WHO) recommends either of them to MDR-TB regimen.

The Head of Division of Leprosy, Tuberculosis and Lung Disease (NTLD) in Kenya Dr. Maureen Kameme, says that only patients with XDR-TB are chosen for the drug pilot.

Data from the National Tuberculosis, Leprosy and Lung Disease programme shows that Kenya recorded 3,000 cases of drug-resistant tuberculosis.

However, there are plans to expand prescription to patients with MDR-TB, with 300 to 500 patients expected to put on the drugs every year.

Kenya through the National Tuberculosis, Leprosy and Lung Disease Programme has established to Put 650 patients on new drugs by the end of the year.

A dose of both Bedaquiline and Delamanid costs Kshs.50, 000, the TB programme have embarked on a small number of patients this year and it is looking forward to enrolling more patients in the coming years gradually.

Currently, Kangemi Health Centre has two MDR-TB patients, one is almost finishing treatment and the other one was admitted at the TB clinic last Month. All due processes and procedures are underway to be enrolled in the National TB programme with the new regimens.

Calvin



posted by resultsjp at 21:36| Comment(3) | 情報
この記事へのコメント
先進的な取り組みです。日本の支援も益々期待されますね。
Posted by ひら at 2018年10月09日 09:41
デラマニドが採用されて、ますます日本の知見が広がりますね
Posted by ことり at 2018年10月09日 10:38
使用拡大により価格を下げられれば、他への波及も期待できますね。
Posted by しん at 2018年10月12日 07:32
コメントを書く
お名前: [必須入力]

メールアドレス: [必須入力]

ホームページアドレス:

コメント: [必須入力]